Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates [Yahoo! Finance]
Alnylam Pharmaceuticals, Inc. (ALNY)
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.alnylam.com/investor-overview
Company Research
Source: Yahoo! Finance
Meanwhile, mergers and acquisitions continued to be in the spotlight. Recap of the Week's Most Important Stories Alnylam Skyrockets on Study Success : Alnylam Pharmaceuticals reported positive top-line results from the phase III HELIOS-B study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic, for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The stock skyrocketed in response to the success of the study. The phase III HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in the overall population as well as the monotherapy population. The study also demonstrated statistically significant improvements across all secondary endpoints in both the overall and monotherapy populations. Key measures of disease progression, such as the six-minute walk test, Kansas City Cardiomyopathy Questionnaire and New York Heart Assoc
Show less
Read more
Impact Snapshot
Event Time:
ALNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALNY alerts
High impacting Alnylam Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ALNY
News
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at UBS Group AG from $253.00 to $288.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Stifel Nicolaus from $215.00 to $295.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Citigroup Inc. from $227.00 to $291.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Bank of America Co. from $248.00 to $295.00. They now have a "buy" rating on the stock.MarketBeat
- Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at TD Cowen from $260.00 to $282.00. They now have a "buy" rating on the stock.MarketBeat
ALNY
Earnings
- 5/2/24 - Beat
ALNY
Sec Filings
- 6/27/24 - Form 4
- 6/26/24 - Form 4
- 6/26/24 - Form 4
- ALNY's page on the SEC website